HOME ·

06990.HK

SKB BIO (06990.HK): seventh sac-TMT indication filing accepted, first-line PD-L1-negative non-squamous NSCLC
Tags：
SKB BIO06990.HKNew Drug Application
2026-10-27
SKB BIO (06990.HK): ESMO Data for Sac-TMT in Two Phase III Lung Cancer Studies
Tags：
NewTimeSpaceSKB BIO06990.HK
2026-10-25
SKB BIO (06990.HK): Positive Phase II Interim Results for SKB378/WIN378 in Asthma; Phase III Initiated
Tags：
SKB BIO06990.HKR&D Progress
2026-09-08
SKB BIO(06990.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 388.01 million, turned profitable from a loss YoY
Tags：
SKB BIO06990.HKturned profitable from loss
2026-08-18
SKB BIO (06990.HK): NMPA Accepts sNDA for Core Product Sac-TMT in First-Line TNBC Treatment
Tags：
SKB BIO06990.HKPriority Review
2026-07-30
SKB BIO (06990.HK) plans to issue in total 5.84 million shares by placement, with estimated net proceeds of HKD 2.72 billion
Tags：
SKB BIO06990.HKNewTimeSpace
2026-07-08
SKB BIO-B(06990.HK): Proposed Placing of 5.838 Million New H-Shares, Estimated Net Proceeds of Approximately HK$2.723 Billion
Tags：
SKB BIO-B06990.HKH-share placement
2026-07-08
SKB BIO-B(06990.HK): Joint Company Secretary Chung Ming Fai Resigns; Zhou Zejian to Serve as Sole Company Secretary
Tags：
SKB BIO-B06990.HKresignation
2026-07-07
KELUN-B (06990.HK): Two Registration Studies Selected for Oral Presentations at 2026 ASCO; Sac-TMT Shows Stellar Frontline NSCLC Data
Tags：
KELUN-B06990.HKASCO
2026-05-22
SKB BIO-B(06990.HK): Core Product Approved for Fourth Indication, Boosting Breast Cancer Treatment Layout
Tags：
SKB BIO-B06990.HK
2026-02-06
SKB BIO-B(06990.HK): TROP2 ADC Combined with Immunotherapy Gets Breakthrough Designation, Accumulating Five Relevant Qualifications
Tags：
SKB BIO-B06990.HKinnovative drug
2026-01-05